Cotización UroGen Pharma - URGN

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

11.63

Postura de Compra

11.62

Postura de Venta

11.66

Volume Operado de la Acción

248,763

11.31 Rango del Día 11.82

10.6001 Rango de 52 semanas 20.70

Capitalización de Mercado [m]

490.779M

Precio Anterior

11.45

Precio de Apertura

11.53

Hora

11.6696

Última hora de negociación

14:16:55

Volumen financiero

US$ 2,892,607

Precio Promedio Ponderado

11.628

Volumen promedio (3 m)

591,124

Acciones en circulación

42,199,414

Rendimiento del Dividendo

Ratio Precio/Utilidad

-4.81

Beneficio por acción (BPA)

-2.42

turnover

82.71M

Beneficio neto

-102.24M

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.urogen.com

Sede

Ra'anana, Center, Isr

Fundado

UroGen Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker URGN. The last closing price for UroGen Pharma was US$11.45. Over the last year, UroGen Pharma shares have traded in a share price range of US$ 10.6001 to US$ 20.70.

UroGen Pharma currently has 42,199,414 shares in issue. The market capitalisation of UroGen Pharma is US$483.18 million. UroGen Pharma has a price to earnings ratio (PE ratio) of -4.81.

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

New Drug Application for UGN-102 accepted by US FDA; PDUFA target action date set for June 13, 2025 JELMYTO® achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in...

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

Fireside Chat on November 12, 2024 at 3:00 PM ET UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

Conference Call and Webcast Scheduled for Wednesday, November 6, 2024, at 10:00AM ET UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative...

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

The Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% Patients Receiving UGN-102 had a 79.6% Complete Response...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.46	-3.80479735318	12.09	12.34	10.62	510257	11.27787047	CS
4	-0.5	-4.12201154163	12.13	13.33	10.62	469644	12.04794167	CS
12	-2.61	-18.3286516854	14.24	14.57	10.62	591124	12.61052574	CS
26	-1.24	-9.63480963481	12.87	20.7	10.62	623773	14.57823045	CS
52	-0.66	-5.37021969081	12.29	20.7	10.6001	474796	14.83561457	CS
156	-0.47	-3.88429752066	12.1	24.13	4.85	294757	14.0505619	CS
260	-17.61	-60.2257181943	29.24	35.21	4.85	242707	16.2152725	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
WORXSCWorx Corporation	US$ 2.135 (117.86%)	134.47M
CRNCCerence Inc	US$ 5.8199 (106.38%)	72.76M
ARQQArqit Quantum Inc	US$ 10.54 (43.60%)	762.64k
SPAISafe Pro Group Inc	US$ 4.55 (42.19%)	42M
PROCProcaps Group SA	US$ 0.785 (37.36%)	1.23M
SKKSKK Holdings Limited	US$ 0.8208 (-82.00%)	28.75M
WCTWellchange Holdings Company Limited	US$ 1.23 (-62.95%)	1.97M
TMTCTMT Acquisition Corporation	US$ 2.40 (-62.73%)	371.32k
TMTCUTMT Acquisition Corporation	US$ 2.99 (-55.24%)	11.76k
GLXGGalaxy Payroll Group Ltd	US$ 1.79 (-54.22%)	2.24M
CDTConduit Pharmaceuticals Inc	US$ 0.1054 (14.19%)	555.92M
NVDANVIDIA Corporation	US$ 148.3124 (1.66%)	330.41M
ELABElevai Labs Inc	US$ 0.02015 (-5.84%)	222.67M
AKTSAkoustis Technologies Inc	US$ 0.103 (18.25%)	200.72M
MARAMARA Holdings Inc	US$ 24.56 (8.53%)	142.11M